Edition:
India

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

0.82USD
21 Nov 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.82
Open
$0.89
Day's High
$0.93
Day's Low
$0.81
Volume
68,062
Avg. Vol
77,047
52-wk High
$6.55
52-wk Low
$0.71

Latest Key Developments (Source: Significant Developments)

Adaptimmune Qtrly Loss Per Share $0.06
Wednesday, 6 Nov 2019 

Nov 6 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.QTRLY REVENUE $0.2 MILLION VERSUS $40.8 MILLION.SEES EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND CURRENT OPERATIONS THROUGH Q3 OF 2020.QTRLY LOSS PER SHARE $0.06.ADAPTIMMUNE -FACTORS RAISE SUBSTANTIAL DOUBT ABOUT ABILITY TO CONTINUE AS A GOING CONCERN FOR AT LEAST 1 YEAR FROM ISSUANCE OF SEPT 30 QTRLY STATEMENTS.IN IMMEDIATE FUTURE, COMPANY PLANS TO CONTINUE TO PRIORITIZE AND REVIEW ONGOING CLINICAL DEVELOPMENT PROJECTS AND COSTS.AIMS TO FOCUS OPERATIONS ON ADP-A2M4 SPEARHEAD-1, ADP-A2M4CD8 SURPASS, AND ADP-A2AFP TRIALS IN IMMEDIATE FUTURE.Q3 EARNINGS PER SHARE VIEW $-0.31, REVENUE VIEW $1.5 MILLION -- REFINITIV IBES DATA.  Full Article

Adaptimmune Reports Second Quarter 2019 Financial Results And Business Update
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.ADAPTIMMUNE THERAPEUTICS PLC - QTRLY REVENUE WAS $0.2 MILLION VERSUS $9.0 MILLION.ADAPTIMMUNE THERAPEUTICS PLC - QTRLY LOSS PER SHARE $0.07.ADAPTIMMUNE THERAPEUTICS - EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND COMPANY'S CURRENT OPERATIONS THROUGH Q3 OF 2020.  Full Article

New Executive Team Announced At Adaptimmune
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Adaptimmune Therapeutics PLC ::NEW EXECUTIVE TEAM ANNOUNCED AT ADAPTIMMUNE.ADAPTIMMUNE THERAPEUTICS PLC - ADRIAN RAWCLIFFE TO ASSUME CEO ROLE FROM SEPTEMBER 1, 2019.ADAPTIMMUNE THERAPEUTICS PLC - RAFAEL AMADO, PRESIDENT RESEARCH AND DEVELOPMENT, WILL LEAVE COMPANY ON AUGUST 12, 2019.ADAPTIMMUNE THERAPEUTICS PLC - COMPANY IS RECRUITING A CHIEF MEDICAL OFFICER AND A CHIEF FINANCIAL OFFICER.  Full Article

Adaptimmune Starts Trial with ADP-A2M4 SPEAR T‑cells For Patients With Synovial Sarcoma
Thursday, 25 Jul 2019 

July 25 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE STARTS SPEARHEAD-1 TRIAL WITH ADP-A2M4 SPEAR T-CELLS FOR PATIENTS WITH SYNOVIAL SARCOMA OR MRCLS.ADAPTIMMUNE THERAPEUTICS PLC - COMPELLING DATA REPORTED WITH ADP-A2M4 SPEAR T-CELLS IN SYNOVIAL SARCOMA -.ADAPTIMMUNE THERAPEUTICS PLC - ADAPTIMMUNE PLANS TO LAUNCH A TCR T-CELL THERAPY IN 2022 -.  Full Article

Adrian Rawcliffe To Succeed James Noble As Adaptimmune Chief Executive Officer
Thursday, 27 Jun 2019 

June 27 (Reuters) - Adaptimmune Therapeutics PLC ::ADRIAN RAWCLIFFE TO SUCCEED JAMES NOBLE AS ADAPTIMMUNE CHIEF EXECUTIVE OFFICER.ADAPTIMMUNE THERAPEUTICS - TRANSITION TO OCCUR WHEN JAMES RETIRES FROM EXECUTIVE DUTIES, TRANSITIONS TO NON-EXECUTIVE DIRECTOR ROLE ON BOARD ON SEPT 1.ADAPTIMMUNE THERAPEUTICS PLC - COMPANY HAS STARTED A GLOBAL SEARCH FOR A NEW CFO, WHICH WILL BE SUBJECT OF A SEPARATE ANNOUNCEMENT..ADAPTIMMUNE THERAPEUTICS - ADRIAN RAWCLIFFE, CURRENTLY CHIEF FINANCIAL OFFICER OF COMPANY, WILL SUCCEED JAMES NOBLE AS CHIEF EXECUTIVE OFFICER.  Full Article

Adaptimmune Therapeutics - Significant Clinical Progress As Adaptimmune Announces Responses With ADP-A2m4 In Synovial Sarcoma And Antitumor Activity In Other Solid Tumors
Monday, 6 May 2019 

May 6 (Reuters) - Adaptimmune Therapeutics PLC ::SIGNIFICANT CLINICAL PROGRESS AS ADAPTIMMUNE ANNOUNCES RESPONSES WITH ADP-A2M4 IN SYNOVIAL SARCOMA AND ANTITUMOR ACTIVITY IN OTHER SOLID TUMORS.ADAPTIMMUNE - ANNOUNCED CLINICAL PROGRESS WITH PARTIAL RESPONSES IN 4/5 SYNOVIAL SARCOMA PATIENTS TREATED WITH ABOUT 10 BILLION CELLS IN ADP-A2M4 PILOT STUDY.ADAPTIMMUNE THERAPEUTICS - WILL INITIATE SPEARHEAD-1 TRIAL IN PATIENTS WITH SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA (MRCLS) LATER THIS YEAR.  Full Article

Adaptimmune Therapeutics Reports Quarterly Loss Per Ordinary Share Of $0.05
Thursday, 15 Mar 2018 

March 15 (Reuters) - Adaptimmune Therapeutics Plc ::ADAPTIMMUNE REPORTS FOURTH QUARTER / FULL YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE.ADAPTIMMUNE THERAPEUTICS PLC QUARTERLY LOSS PER ORDINARY SHARE $0.05.ADAPTIMMUNE THERAPEUTICS - BELIEVES EXISTING CASH AND CASH EQUIVALENTS, SHORT-TERM DEPOSITS TO FUND CURRENT OPERATING PLAN THROUGH TO EARLY 2020.ADAPTIMMUNE THERAPEUTICS PLC QUARTERLY REVENUE $4.3 MILLION VERSUS $8.5 MILLION.  Full Article

Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc ::ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING.ADAPTIMMUNE THERAPEUTICS - AGREEMENT IS FOR TERM OF 5 YEARS WITH EARLIER TERMINATION AVAILABLE TO BOTH PARTIES ON PROVISION OF 12 MONTHS' NOTICE.ADAPTIMMUNE THERAPEUTICS PLC - AGREEMENT WILL ENABLE CO TO HAVE ITS OWN DEDICATED VECTOR MANUFACTURING SPACE IN UK.ADAPTIMMUNE - AGREEMENT TO ENSURE VECTOR SUPPLY PRODUCTION BEYOND 2020 FOR ONGOING STUDIES WITH 3 SPEAR T-CELL THERAPIES, MAGE-A4, MAGE-A10 AND AFP.  Full Article

Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc :::ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN OBSERVED.ADAPTIMMUNE - IN NSCLC STUDY, THERE HAS BEEN ONE SERIOUS ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME, A GRADE 4 EVENT THAT RESOLVED WITH TREATMENT.ADAPTIMMUNE THERAPEUTICS PLC - ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME IN NSCLC STUDY LED TO COHORT 1 EXPANSION FROM 3 TO 6 PATIENTS.  Full Article